Bambusa Therapeutics Inc., a Boston-based biotech startup founded in 2024, filed for an initial public offering to fund clinical trials of its eczema and inflammation disorder drugs. The company is developing long-acting bispecific antibodies targeting the global immunology and inflammation market, estimated at over $150 billion annually. Bambusa secured its lead candidates by acquiring assets from a unit of BioNTech SE, the first to treat atopic dermatitis and the second for respiratory and allergic diseases.
Co-founder Shanshan Xu, a former BioNTech executive, beneficially owns 21.5% of the company. Major investors include RA Capital Management, Salvia Investment, BVF Partners, KKR Dawn Biopharma, and INCE Capital. The firm recently completed a $33.1 million funding round, valuing the company at a significant step-up from its prior $89 million raise.
As of June 30, 2026, Bambusa held $71.5 million in cash while reporting a net loss of $22.4 million on no revenue for the first half of the year. The IPO will be led by Bank of America, Evercore, UBS, and Cantor Fitzgerald, with shares planned for trading on the Nasdaq Global Select Market under the symbol BBTX.
Source: Bloomberg Markets · Summarized by HeadlinesBriefing